Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Rule 8.3- Torex Retail PLC

14 Jun 2005 11:59

Jupiter Asset Management Limited14 June 2005 FORM 8.3 DEALINGS BY PERSONS WHO OWN OR CONTROL 1% OR MORE OF ANY CLASS OF RELEVANT SECURITY (Rule 8.3 of The City Code on Takeovers and Mergers) Name of purchaser/vendor * JUPITER ASSET MANAGEMENT LIMITED Company dealt in TOREX RETAIL PLC Relevant security dealt in CFDs If a connected EFM, name of offeree/offeror with which connected N/A If a connected EFM, nature of connection # N/A Date of dealing 13TH JUNE 2005 DEALINGS + Amount bought Price per unit (currency must be stated) Amount sold Price per unit (currency must be stated) Resultant total amount and percentage of the same relevant 7,418,005 (4.07%) ORDINARY SHARESsecurity owned or controlled 1,154,400 (0.63%) CFDs IS A SUPPLEMENTAL FORM 8 (DERIVATIVE)/FORM 8 (OPTION) ATTACHED? YES Date of disclosure 14TH JUNE 2005 Contact name JENNY THOMPSON Telephone number 020 7314 5565 * Specify the owner or controller in addition to the person dealing. The naming of nominees or vehicle companies is insufficient. In the case of disclosure of dealings by fund managers on behalf of discretionary clients, the clients need not be named.# See the definition of "connected fund managers and principal traders" in the Definitions Section of the Code.+ If disclosing dealings/holdings in derivatives or options, please attach Supplemental Form 8 (Derivative) or Supplemental Form 8 (Option), as appropriate. For details of the Code's dealing disclosure requirements, see Rule 8 and itsNotes which can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk. SUPPLEMENTAL FORM 8 (DERIVATIVE) DEALINGS/HOLDINGS IN DERIVATIVES (This form should be attached to Form 8.1, Form 8.1(b)(ii), Form 8.2 or Form 8.3, as appropriate) Description of all derivative products disclosed on this form CONTRACT FOR DIFFERENCE Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. NONE WRITING/ENTERING INTO A DERIVATIVE Product name Transaction Writing/entering Number of Reference Maturity eg long CFD date into (indicate securities price date as applicable) to which the (currency derivative is must be referenced stated) LONG CFD 13TH JUNE 2005 ENTERED INFO 61,000 ÂŁ0.97097 OPEN ENDEDLONG CFD 13TH JUNE 2005 ENTERED INFO 14,000 ÂŁ0.97097 OPEN ENDED LONG CFD 13TH JUNE 2005 ENTERED INFO 25,000 ÂŁ0.97097 OPEN ENDED CLOSING OUT A DERIVATIVE Product name Transaction Number of securities Reference Closing out price eg long CFD date to which the price (currency must be derivative is (currency stated) referenced must be stated) DETAILS OF OPEN DERIVATIVES (excluding any transaction set out above) Product name Transaction Written/entered Number of Reference Maturity eg long CFD date into (indicate securities to price date as applicable) which the (currency derivative is must be referenced stated) LONG CFD 5TH MAY 2005 ENTERED INFO 100,000 ÂŁ0.985985 OPEN ENDED LONG CFD 1ST AUGUST 2004 ENTERED INFO 75,000 ÂŁ0.585585 OPEN ENDEDLONG CFD 23RD APRIL 2004 ENTERED INFO 164,400 ÂŁ0.6006 OPEN ENDEDLONG CFD 24TH MARCH 2005 ENTERED INFO 25,000 ÂŁ1.14114 OPEN ENDEDLONG CFD 9TH MARCH 2005 ENTERED INFO 30,000 ÂŁ1.1011 OPEN ENDEDLONG CFD 2ND MARCH 2005 ENTERED INFO 300,000 ÂŁ1.015 OPEN ENDEDLONG CFD 6TH JUNE 2005 ENTERED INFO 185,000 ÂŁ1.06106 OPEN ENDEDLONG CFD 10TH JUNE 2005 ENTERED INFO 100,000 ÂŁ1.00529 OPEN ENDEDLONG CFD 10TH JUNE 2005 ENTERED INFO 45,000 ÂŁ1.00529 OPEN ENDEDLONG CFD 10TH JUNE 2005 ENTERED INFO 30,000 ÂŁ1.00529 OPEN ENDED For details of the Code's dealing disclosure requirements, see Rule 8 and its Notes which can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jan 20267:00 amRNSSecondary Trading Following Cancellation
7th Jan 20267:00 amRNSCancellation - Tissue Regenix Group Plc
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
17th Dec 20256:00 pmRNSTissue Regenix Group
8th Dec 20257:00 amRNSUpdate re. proposed cancellation of shares
4th Dec 20252:40 pmRNSProposed £17.5m CLN raise, cancellation of Trading
1st Dec 20257:00 amRNSFurther re. financial update and funding plans
7th Nov 20257:00 amRNSFinancial update and funding plans
22nd Oct 20253:29 pmRNSStatement re. Suspension
22nd Oct 20252:02 pmRNSSuspension - Tissue Regenix Group PLC
17th Oct 20257:00 amRNSCFO joins Board
16th Oct 20257:00 amRNSUpdate re. FY24 & H125 restatement & Board Changes
9th Oct 20257:00 amRNSHolding(s) in Company
6th Oct 20253:29 pmRNSHolding(s) in Company
3rd Oct 20253:01 pmRNSHolding(s) in Company
2nd Oct 20254:43 pmRNSHolding(s) in Company
1st Oct 20255:35 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
17th Sep 20257:00 amRNSNotice of Results
8th Sep 20257:01 amRNSHalf-Year Trading Update and Notice of Results
8th Sep 20257:00 amRNSBoard Changes
1st Aug 20257:00 amRNSDirectorate Change
23rd Jul 20251:52 pmRNSResult of AGM
4th Jul 20257:00 amRNSGrant of share options
27th Jun 20257:00 amRNSPosting of Annual Report & Notice of AGM
25th Jun 20257:00 amRNSFinal results for the year ended 31 December 2024
9th Jun 20257:00 amRNSCE & UKCA certification for OrthoPure® XT
24th Apr 20259:38 amRNSForm 8.5 (EPT/NON-RI)- Tissue Regenix Group Plc
15th Apr 20259:23 amRNSForm 8.5 (EPT/NON-RI)
10th Apr 20259:09 amRNSForm 8.5 (EPT/NON-RI)
9th Apr 202510:45 amRNSForm 8.5 (EPT/NON-RI)
8th Apr 20257:00 amRNSConclusion of Strategic Review & Offer Period
7th Apr 20258:46 amRNSForm 8.5 (EPT/NON-RI)
1st Apr 20259:12 amRNSForm 8.5 (EPT/NON-RI)
31st Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
27th Mar 20257:00 amRNSEuropean patent granted
25th Mar 20258:58 amRNSForm 8.5- Tissue Regenix Group Plc
21st Mar 20258:36 amRNSForm 8.5 (EPT/NON-RI)
20th Mar 20259:19 amRNSForm 8.5 (EPT/NON-RI)
19th Mar 20258:55 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20257:00 amRNSCompany update
12th Mar 20259:27 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 20259:30 amRNSForm 8.5 (EPT/NON-RI)
6th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
5th Mar 20258:54 amRNSForm 8.5 (EPT/NON-RI)
4th Mar 20259:28 amRNSForm 8.5 (EPT/NON-RI)
3rd Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 20258:56 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.